Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical decision analysis for personalized oncology at the patient bedside.

Tumori·2026
Same author

Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

The sacral chordoma margin.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2020
Same author

Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.

Oral oncology·2019
Same author

Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study.

BMC pediatrics·2019
Same author

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

Breast cancer research and treatment·2018

Related Experiment Video

Updated: Jul 12, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Hematologic parameters during treatment with high-dose medroxyprogesterone acetate.

F Brema, M A Queirolo, L Canobbio

    Tumori
    |March 1, 1981
    PubMed
    Summary

    High-dose medroxyprogesterone acetate (MPA) in advanced breast cancer patients did not significantly increase thrombotic risk. While some clotting markers shifted towards hypercoagulability, they remained within normal limits, suggesting MPA is safe at oral doses without other risk factors.

    More Related Videos

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
    06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    Related Experiment Videos

    Last Updated: Jul 12, 2026

    In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
    05:32

    In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

    Published on: February 16, 2024

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
    06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    Area of Science:

    • Oncology
    • Hematology
    • Pharmacology

    Background:

    • Advanced breast cancer poses risks, and treatments may influence coagulation.
    • Medroxyprogesterone acetate (MPA) is used in cancer therapy.
    • Understanding MPA's impact on blood clotting is crucial for patient safety.

    Purpose of the Study:

    • To evaluate the effect of high-dose oral MPA on blood clotting and platelet aggregation in postmenopausal women with advanced breast cancer.
    • To assess the thrombotic risk associated with MPA treatment.

    Main Methods:

    • 12 postmenopausal patients with advanced breast cancer received oral MPA (800 mg/day) for at least 3 months.
    • Blood clotting parameters, platelet aggregation, complete blood count, and lipid profiles were monitored.
    • Laboratory tests included PTT, TEG, antithrombin III, and platelet adhesiveness.

    Main Results:

    • Statistically significant changes were observed in PTT, TEG, antithrombin III, and platelet adhesiveness.
    • These changes indicated a trend towards hypercoagulability.
    • However, average values did not exceed the upper normal range, suggesting no clinically significant thrombotic activity.

    Conclusions:

    • High-dose oral MPA (800 mg/day) does not appear to cause clinically relevant thrombotic activity in advanced breast cancer patients.
    • MPA can be considered safe regarding thrombotic risk at these doses when no additional risk factors are present.